Women with an inherited BRCA1 mutation have an increased risk of breast and ovarian cancer. This type of tumour depends on the protein EXO1 to survive. Thanks to a KWF grant, Sebastian Pomplun, together with geneticist Sylvie Noordermeer, is investigating new inhibitors to disable this protein.
Read more&width=710&height=710)
A driving force
LUMC strongly underpins the idea that ‘Science is the driving force behind innovative healthcare’. Outcomes of top level fundamental, translational and clinical research by LUMC researchers form a strong basis for innovative and qualitative healthcare on a national, European and international level.
A real game changer was the development of the Dutch national research agenda (NWA) in 2015. The agenda reveals the complexity of the issues challenging Dutch society today. These issues are clustered in so called routes. LUMC is involved in many of these routes and contributes this way to solving important societal challenges.